Rocket Lab's Regulatory Crossfire: SpaceX's FCC Challenge Casts a Shadow Over the Iridium Deal

Rocket Lab's $8B Iridium acquisition faces regulatory scrutiny, while Q2 revenue jumps 62% but cash burn and dilution weigh on shares.

There's a certain irony in the space industry: those who shout "competition" the loudest often mean the opposite. Last week, SpaceX petitioned the US Federal Communications Commission to scrutinize Iridium's business practices as part of the regulatory review of Rocket Lab's proposed acquisition of the satellite operator. The stated rationale? Iridium has a "well-documented history of anti-competitive attacks against competitors and American consumers." It sounds like consumer protection—but it's really another move in the high-stakes contest for dominance in orbit.

For Rocket Lab shareholders, this isn't an academic question. The roughly $8 billion acquisition of Iridium Communications—half cash, half stock—includes a variable exchange ratio. How many Rocket Lab shares Iridium's owners ultimately receive depends on Rocket Lab's average stock price shortly before the deal closes. Any regulatory delay, any weakness in the share price, directly impacts the terms of the largest transaction in the company's history. Regulation and stock performance feed each other—a dynamic that will shadow investors in the months ahead.

Operations Keep Humming Despite the Noise

While lawyers and lobbyists battle over the merger, the operational engine keeps turning, almost defiantly. On Wednesday, the 94th Electron rocket lifted off from Launch Complex 1 in New Zealand, carrying another Earth-observation satellite for Japanese customer Synspective—the 15th mission of the year. That launch, dubbed "Owl Around The World," placed a StriX satellite into a 575-kilometer orbit and snapped a three-day losing streak for the stock.

Fresh contracts have also arrived from the US Space Force: a slot in the "Space Data Network Consortium" with initial orders worth $12 million, plus inclusion in the multibillion-dollar NITE-STAR IDIQ framework program. Viasat has likewise selected Rocket Lab as the satellite bus supplier for a military program. This flurry of announcements underscores how far Rocket Lab has diversified—from small launch provider to systems house serving government agencies, the military, and commercial operators alike.

That diversification is the core strategic logic behind the Iridium acquisition. A satellite operator with 66 active L-band satellites and roughly 2.55 million subscribers would transform Rocket Lab from a pure launch company into an integrated space and communications enterprise.

Strong Numbers—But a Clouded Outlook

The second-quarter results provided tailwind for that transition narrative: $234 million in revenue, up 62 percent year over year, and a backlog of $2.36 billion—more than double what it was a year ago. The operating loss of $8.8 million came in well below the company's own guidance. For the third quarter, management projects revenue between $250 million and $265 million.

Yet the picture is more nuanced. Free cash flow remains deeply negative: minus $110.1 million in Q2, following minus $77.4 million in Q1. Gross margin is expected to dip to 29 to 31 percent in the third quarter, down from 36.1 percent in the prior quarter. The net loss of $49.26 million was smaller than in earlier quarters, but the cash burn tells a different story.

Meanwhile, the Neutron rocket—Rocket Lab's answer to larger payloads and potentially a Falcon 9 competitor—still awaits its first launch. A 2026 launch window looks increasingly unlikely, which also explains the delayed MIT Venus mission that explicitly awaits "Neutron readiness."

Insider Sales and a Dilution Overhang

Adding to the sentiment pressure, several executives have sold shares in recent weeks—COO Frank Klein, Chief Legal Officer Arjun Kampani, and President Marvin Bradford Clevenger, mostly under pre-arranged trading plans or to cover tax obligations from vesting equity. CFO Adam Spice disposed of shares worth roughly $8.8 million, and Director Saintil transferred a six-figure share position into a trust. These automated sales are governed by 10b5-1 plans and are not alarm signals per se—but they arrive at a delicate moment.

Rocket Lab has simultaneously established a roughly $1.94 billion equity program to fund the cash portion of the Iridium acquisition and reduce the promised $3.6 billion bridge financing. That means additional share supply that could pressure the stock.

The market has responded with nervous movement: since the May peak, the shares have lost nearly 60 percent, trading well below all major moving averages, with a Relative Strength Index around 35 indicating oversold conditions. The stock sits at roughly $54.90, almost 60 percent below its 52-week high of $133.80, though still comfortably above the year's low of $32.60. The 30-day decline of 15 percent and the depressed RSI could support technical rebounds—but they don't address the underlying valuation question.

The NASA Setback and the Valuation Conundrum

This same week brought a strategic disappointment: NASA awarded Mars communication contracts worth up to $700 million to Blue Origin instead of Rocket Lab. The stock dipped about two percent—manageable, but symptomatic of a recurring pattern: big ambitions, yet the marquee contracts land elsewhere.

Rocket Lab has established itself as a reliable niche provider for small to medium payloads, but the leap into the major leagues of space contracting remains elusive. While SpaceX operates in entirely different dimensions with its Starship test campaign and a backlog of $47.5 billion, Rocket Lab still fights for every major contract award.

The valuation math remains the sorest point. Rocket Lab trades at roughly 49 times revenue, according to market observers—versus a fair multiple of about 11 and an industry average of 4.2. Even with an enterprise value of $12.7 billion and 27 times expected 2026 revenue, the stock carries ambitious pricing, despite analysts projecting annual revenue growth of 43 percent through 2028 and EBITDA breakeven by 2027.

Bank of America trimmed its price target from $115 to $110 on September 1 but maintained its buy rating—a signal that the fundamental growth story remains intact, even if the road to Iridium integration proves rockier than hoped.

What to Watch

The special shareholder meeting of Iridium scheduled for September 24 will reveal whether the acquisition target's owners approve the deal—a date the market will likely watch more closely than any single Electron mission. For those looking ahead, the key question isn't how many rockets launch in the coming months, but how quickly the regulatory cloud over the company's largest-ever deal begins to lift.